PlumX Metrics
Embed PlumX Metrics

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib

Clinical Pharmacology: Advances and Applications, ISSN: 1179-1438, Vol: 14, Page: 1-9
2022
  • 10
    Citations
  • 0
    Usage
  • 14
    Captures
  • 2
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

Precision medicine is continuing to redefine how we approach cancer treatment and advance the oncology treatment landscape at an unprecedented rate – especially for lung

Review Description

Rearrangement of anaplastic lymphoma kinase (ALK) gene is detected in approximately 5% of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors targeting ALK have significantly improved the prognosis of these patients. However, most patients experienced disease progression within a few years due to acquired resistance. Brigatinib is a second-generation ALK inhibitor effective in presence of several ALK mutations with demonstrated activity against central nervous system metastases. Currently, brigatinib is approved to treat ALK-positive metastatic NSCLC patients not previously treated with ALK inhibitors and patients who have progressed on or are intolerant to crizotinib. In this review, we provide a summary of results from clinical trials involving brigatinib, and we discuss its possible role in the management of ALK-positive NSCLC in the following years.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know